老虎证券

BRIEF-Unprecedented Results From The Phase 3 MajesTEC-3 Study Support TECVAYLI Plus DARZALEX FASPRO As A Potential Standard Of Care As Early As Second Line For Patients With Relapsed/Refractory Multiple Myeloma

Reuters
2025/12/09
BRIEF-Unprecedented Results From The Phase 3 MajesTEC-3 Study Support TECVAYLI Plus DARZALEX FASPRO As A Potential Standard Of Care As Early As Second Line For Patients With Relapsed/Refractory Multiple Myeloma

Dec 9 (Reuters) - Johnson & Johnson JNJ.N:

  • UNPRECEDENTED RESULTS FROM THE PHASE 3 MAJESTEC-3 STUDY SUPPORT TECVAYLI® PLUS DARZALEX FASPRO® AS A POTENTIAL STANDARD OF CARE AS EARLY AS SECOND LINE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

  • J&J - TECVAYLI AND DARZALEX SHOW SIGNIFICANT SURVIVAL ADVANTAGE

  • J&J - SUBMITS SBLA FOR TECVAYLI AND DARZALEX COMBINATION AS TREATMENT FOR RRMM

Source text: ID:nPn84198Ca

Further company coverage: JNJ.N

((Reuters.Briefs@thomsonreuters.com;))

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10